Cutler L - Search Results

1

Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.

Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. Summerfield SG, et al. Among authors: cutler l. J Pharmacol Exp Ther. 2006 Mar;316(3):1282-90. doi: 10.1124/jpet.105.092916. Epub 2005 Dec 5. J Pharmacol Exp Ther. 2006. PMID: 16330496

2

Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.

Cutler L, Howes C, Deeks NJ, Buck TL, Jeffrey P. Cutler L, et al. J Pharm Sci. 2006 Sep;95(9):1944-53. doi: 10.1002/jps.20658. J Pharm Sci. 2006. PMID: 16850390

3

Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.

Bassil AK, Taylor CM, Bolton VJ, Gray KM, Brown JD, Cutler L, Summerfield SG, Bruton G, Winchester WJ, Lee K, Sanger GJ. Bassil AK, et al. Among authors: cutler l. Br J Pharmacol. 2009 Sep;158(1):252-8. doi: 10.1111/j.1476-5381.2009.00155.x. Epub 2009 Apr 9. Br J Pharmacol. 2009. PMID: 19371340 Free PMC article.

4

Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase.

Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, Ayrton A, Jeffrey P. Austin NE, et al. Among authors: cutler l. Xenobiotica. 2001 Aug-Sep;31(8-9):677-86. doi: 10.1080/00498250110056531. Xenobiotica. 2001. PMID: 11569533

5

Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.

Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, East P, Hawkins J, Howes C, Hussain I, Jeffrey P, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G. Charrier N, et al. Among authors: cutler l. J Med Chem. 2008 Jun 12;51(11):3313-7. doi: 10.1021/jm800138h. Epub 2008 May 6. J Med Chem. 2008. PMID: 18457381

6

Orexin-A, an hypothalamic peptide with analgesic properties.

Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, Porter RA, Upton N, Hunter AJ, Parsons AA. Bingham S, et al. Among authors: cutler l. Pain. 2001 May;92(1-2):81-90. doi: 10.1016/s0304-3959(00)00470-x. Pain. 2001. PMID: 11323129

7

Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.

Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G. Charrier N, et al. Among authors: cutler l. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3674-8. doi: 10.1016/j.bmcl.2009.03.149. Epub 2009 Apr 5. Bioorg Med Chem Lett. 2009. PMID: 19406640

8

Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.

Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Hussain I, et al. Among authors: cutler l. J Neurochem. 2007 Feb;100(3):802-9. doi: 10.1111/j.1471-4159.2006.04260.x. J Neurochem. 2007. PMID: 17156133 Free article.

9

Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists.

Hall A, Billinton A, Bristow AK, Brown SH, Chowdhury A, Cutler L, Giblin GM, Goldsmith P, Hayhow TG, Kilford IR, Naylor A, Passingham B, Rawlings DA. Hall A, et al. Among authors: cutler l. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4027-32. doi: 10.1016/j.bmcl.2008.05.118. Epub 2008 Jun 5. Bioorg Med Chem Lett. 2008. PMID: 18571922

10

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L. Heightman TD, et al. Among authors: cutler l. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4370-4. doi: 10.1016/j.bmcl.2005.06.042. Bioorg Med Chem Lett. 2005. PMID: 16039851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters